Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia

Modes of response and correlation with markers of HIV replication

P. Cinque, G. Landonio, A. Lazzarin, A. M. Nosari, A. Ruggieri, M. Coen, P. Meraviglia, A. Gringeri, L. Gallo, T. Quirino, E. Santagostino, M. A. Cargnel

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The effects of zidovudine on the platelet count were studied in 152 patients with HIV-related thrombocytopenia of severe grade (platelet count 9/l) and moderate grade (platelet count 50 x 109/l). In both groups of patients there was a significant increase in the mean platelet count from the baseline value, after 2 weeks (from 21 x 109/l to 48 x 109/l and from 75 x 109/l to 97 x 109/l) and 3 months of therapy (to 59 x 109/l and to 144 x 109/l). Sixty-five and 39 patients were followed up for 12 and 18 months, respectively, and the mean platelet values after 12 and 18 months of therapy were still significantly increased, compared to the respective mean baseline values, in both groups of patients. Clinical progression of the disease was observed in 23 treated patients, none of them showing concomitant reductions of the platelet number. An increase in the mean CD4+ cell count after 3 months of therapy was followed by a progressive decline in the 65 patients with a 12-month follow-up, while no significant changes of the p24 antigenemia rates were observed after 1 year of therapy in 53 patients evaluated. The long-term effects of zidovudine on the platelet count, but on other parameters of clinical outcome, might be explained by the involvement of specific mechanisms in the pathogenesis of this kind of thrombocytopenia and of its response to zidovudine.

Original languageEnglish
Pages (from-to)17-21
Number of pages5
JournalEuropean Journal of Haematology
Volume50
Issue number1
Publication statusPublished - 1993

Fingerprint

Zidovudine
Virus Replication
Thrombocytopenia
Platelet Count
HIV
Therapeutics
CD4 Lymphocyte Count
Disease Progression
Blood Platelets

ASJC Scopus subject areas

  • Hematology

Cite this

Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia : Modes of response and correlation with markers of HIV replication. / Cinque, P.; Landonio, G.; Lazzarin, A.; Nosari, A. M.; Ruggieri, A.; Coen, M.; Meraviglia, P.; Gringeri, A.; Gallo, L.; Quirino, T.; Santagostino, E.; Cargnel, M. A.

In: European Journal of Haematology, Vol. 50, No. 1, 1993, p. 17-21.

Research output: Contribution to journalArticle

Cinque, P, Landonio, G, Lazzarin, A, Nosari, AM, Ruggieri, A, Coen, M, Meraviglia, P, Gringeri, A, Gallo, L, Quirino, T, Santagostino, E & Cargnel, MA 1993, 'Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia: Modes of response and correlation with markers of HIV replication', European Journal of Haematology, vol. 50, no. 1, pp. 17-21.
Cinque, P. ; Landonio, G. ; Lazzarin, A. ; Nosari, A. M. ; Ruggieri, A. ; Coen, M. ; Meraviglia, P. ; Gringeri, A. ; Gallo, L. ; Quirino, T. ; Santagostino, E. ; Cargnel, M. A. / Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia : Modes of response and correlation with markers of HIV replication. In: European Journal of Haematology. 1993 ; Vol. 50, No. 1. pp. 17-21.
@article{c4ad325a6e2346cbb94ef985018c006e,
title = "Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia: Modes of response and correlation with markers of HIV replication",
abstract = "The effects of zidovudine on the platelet count were studied in 152 patients with HIV-related thrombocytopenia of severe grade (platelet count 9/l) and moderate grade (platelet count 50 x 109/l). In both groups of patients there was a significant increase in the mean platelet count from the baseline value, after 2 weeks (from 21 x 109/l to 48 x 109/l and from 75 x 109/l to 97 x 109/l) and 3 months of therapy (to 59 x 109/l and to 144 x 109/l). Sixty-five and 39 patients were followed up for 12 and 18 months, respectively, and the mean platelet values after 12 and 18 months of therapy were still significantly increased, compared to the respective mean baseline values, in both groups of patients. Clinical progression of the disease was observed in 23 treated patients, none of them showing concomitant reductions of the platelet number. An increase in the mean CD4+ cell count after 3 months of therapy was followed by a progressive decline in the 65 patients with a 12-month follow-up, while no significant changes of the p24 antigenemia rates were observed after 1 year of therapy in 53 patients evaluated. The long-term effects of zidovudine on the platelet count, but on other parameters of clinical outcome, might be explained by the involvement of specific mechanisms in the pathogenesis of this kind of thrombocytopenia and of its response to zidovudine.",
author = "P. Cinque and G. Landonio and A. Lazzarin and Nosari, {A. M.} and A. Ruggieri and M. Coen and P. Meraviglia and A. Gringeri and L. Gallo and T. Quirino and E. Santagostino and Cargnel, {M. A.}",
year = "1993",
language = "English",
volume = "50",
pages = "17--21",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia

T2 - Modes of response and correlation with markers of HIV replication

AU - Cinque, P.

AU - Landonio, G.

AU - Lazzarin, A.

AU - Nosari, A. M.

AU - Ruggieri, A.

AU - Coen, M.

AU - Meraviglia, P.

AU - Gringeri, A.

AU - Gallo, L.

AU - Quirino, T.

AU - Santagostino, E.

AU - Cargnel, M. A.

PY - 1993

Y1 - 1993

N2 - The effects of zidovudine on the platelet count were studied in 152 patients with HIV-related thrombocytopenia of severe grade (platelet count 9/l) and moderate grade (platelet count 50 x 109/l). In both groups of patients there was a significant increase in the mean platelet count from the baseline value, after 2 weeks (from 21 x 109/l to 48 x 109/l and from 75 x 109/l to 97 x 109/l) and 3 months of therapy (to 59 x 109/l and to 144 x 109/l). Sixty-five and 39 patients were followed up for 12 and 18 months, respectively, and the mean platelet values after 12 and 18 months of therapy were still significantly increased, compared to the respective mean baseline values, in both groups of patients. Clinical progression of the disease was observed in 23 treated patients, none of them showing concomitant reductions of the platelet number. An increase in the mean CD4+ cell count after 3 months of therapy was followed by a progressive decline in the 65 patients with a 12-month follow-up, while no significant changes of the p24 antigenemia rates were observed after 1 year of therapy in 53 patients evaluated. The long-term effects of zidovudine on the platelet count, but on other parameters of clinical outcome, might be explained by the involvement of specific mechanisms in the pathogenesis of this kind of thrombocytopenia and of its response to zidovudine.

AB - The effects of zidovudine on the platelet count were studied in 152 patients with HIV-related thrombocytopenia of severe grade (platelet count 9/l) and moderate grade (platelet count 50 x 109/l). In both groups of patients there was a significant increase in the mean platelet count from the baseline value, after 2 weeks (from 21 x 109/l to 48 x 109/l and from 75 x 109/l to 97 x 109/l) and 3 months of therapy (to 59 x 109/l and to 144 x 109/l). Sixty-five and 39 patients were followed up for 12 and 18 months, respectively, and the mean platelet values after 12 and 18 months of therapy were still significantly increased, compared to the respective mean baseline values, in both groups of patients. Clinical progression of the disease was observed in 23 treated patients, none of them showing concomitant reductions of the platelet number. An increase in the mean CD4+ cell count after 3 months of therapy was followed by a progressive decline in the 65 patients with a 12-month follow-up, while no significant changes of the p24 antigenemia rates were observed after 1 year of therapy in 53 patients evaluated. The long-term effects of zidovudine on the platelet count, but on other parameters of clinical outcome, might be explained by the involvement of specific mechanisms in the pathogenesis of this kind of thrombocytopenia and of its response to zidovudine.

UR - http://www.scopus.com/inward/record.url?scp=0027402764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027402764&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 17

EP - 21

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -